Noida Court Favors Jubilant, Bars Medreich, VS International, Gracure, Jamp India Against Forging Products
Noida Court Favors Jubilant, Bars Medreich, VS International, Gracure, Jamp India Against Forging Products
Observes that the pharmaceutical companies used trade secrets without authorization
A commercial court in Noida has upheld the injunction in favor of Jubilant, barring Medreich Ltd, VS International, Gracure Pharmaceuticals and Jamp India Pharmaceuticals from manufacturing and supplying pharmaceutical products Losartan, Citalopram, and Amlodipine.
The bench noted that Jubilant's proprietary technology and confidential trade secrets were used without authorization, prompting the injunction to protect its intellectual property rights.
(Jamp India, a subsidiary of Jamp Pharma Corporation, Canada, was either directly manufacturing and exporting the products to JAMP Canada or facilitating illegal activities).
The court observed that Jubilant had a prima facie case to protect its literary work against the use without knowledge in India. It said that the balance of convenience favored the plaintiff, which suffered irreparable loss.
Medreich, VS International, Gracure, and Jamp India made several attempts to get the stay vacated and sell more products to Jamp Canada.
While the petitioner was represented by Vaibhav Mittal and Vashistha Parashar, the defendants were guided by Arjun Krishnan.
